Overview
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that focuses on the discovery and development of Smac mimetics, small molecule peptide-mimetic drugs that mimic Smac (Second mitochondrial-derived activator of caspases), for the treatment of cancers. Smac is an endogenous cellular protein that activates the programmed cell death process called apoptosis. Smac activates apoptotic cell death in cancer cells by removing Inhibitor of Apoptosis Proteins (IAPs). IAPs are over-expressed in most cancers and help tumors survive. The central role between Smac and IAPs in cancer cell death renders Smac mimetics a promising new class of cancer therapeutics that are relevant to treating many types of solid tumors and hematological malignancies.
TL32711 is TetraLogic's lead Smac mimetic drug for the treatment of cancers that is entering Phase 2 clinical development. In Phase 1 clinical studies as a single agent and in combination with chemotherapies, TL32711 has demonstrated effective suppression of its molecular target at well-tolerated doses and has shown promising anti-tumor activity.
TetraLogic has strong affiliations and collaborations with top cancer centers and leading medical researchers in the fields of apoptosis and Smac mimetics that support the advancement of the company's programs. TetraLogic owns a large library of Smac mimetics, both dimer and monomer compounds, for the development of follow-on drugs and new indications.
TetraLogic Pharmaceuticals was founded in 2003 with corporate headquarters in Malvern, Pennsylvania.